ADEs are the fourth leading cause of death nationwide, after heart disease, cancer, and stroke. Approximately 5 percent of hospital admissions are due to adverse drug events and patients who experienced ADEs were hospitalized an average of 8 to 12 days longer.
Available research shows that much of the variability observed in patient responses to drug therapies is a result of genetics. Pharmacogenetic testing identifies this variability and helps you in the clinical management of your patients.
Using the results from pharmacogenetic testing, prescribing becomes individualized either through a dose adjustment, or selection of alternative therapy.
This tailored approach results in better efficacy and fewer adverse drug reactions.